Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply. The company makes compounded versions of weight-loss drugs under an FDA rule that applies when the ...
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Shortage of popular drugs Wegovy and Ozempic is over, FDA says.
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
ABC News10d
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
Before Hims & Hers' commercial even aired ... "help-seeking" advertisements." The day after the ad for Hims & Hers' aired during the Super Bowl, on Feb. 10, Novo Nordisk, the maker of ...
Fast Company8d
Hims & Hers markets itself in a very 2025 way: by picking a fight
And the company’s share price is up about 15% since just before the Super Bowl, giving it a valuation of more than $10 billion. Hims & Hers may be taking risks and pushing the regulatory ...
Seeking Alpha9d
Hims & Hers: Firing On All Cylinders, But Expensive
Hims & Hers has shown impressive revenue growth ... followed by 0% for the 12 months after that. For years 3, 4 and 5 we assume a growth rate of 20-25%. We assume that Hims’ weight loss ...
Yahoo Finance8d
Hims & Hers stock sees another spike in trading days after Super Bowl ad
Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the ...
Milwaukee Journal Sentinel12d
Hims & Hers Super Bowl commercial: Ad draws ire from drug industry
Hims & Hers makes its Super Bowl commercial debut in 2025 with a spot for the telehealth company's weight loss medications. Set to the "This Is America" by Childish Gambino (Donald Glover), the ...
Nasdaq9d
Why Hims & Hers Terrifies Big Pharma
The video was published on Feb. 12, 2025. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best ...
Yahoo10d
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
Super Bowl commercial in which telehealth company Hims & Hers hyped up compounded weight-loss drugs, which aren’t FDA-approved. The fallout has become political, too. Two days before the Super ...
Modern Healthcare11d
Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad
After telehealth brand ... The “Check before you inject” ad specifically calls out compounded medications, which is the type that Hims & Hers manufactures and is not FDA approved.